Search

The Box-Behnken experimental design and response surface methodology were employed to optimize the preparation of the aspirin micro-porous osmotic pump tablets. The core of the tablet was prepared with aspirin and β-CD inclusion, then osmotic pump tablets were obtained by coating a layer of cellulose acetate containing PEG 4000 as porogenic agent. The in vitro release test shows that the aspirin inclusion complex microporous osmotic pump tablets prepared by this process has a cumulative release rate of 1. 5% and 1. 6% within 0 ~2 h in artificial gastric juice compared to commercially available aspirin enteric coated tablets. After adjusting the release medium to pH 6. 8, there is no significant difference in the cumulative drug release between the two formulations at 10 h. And the inclusion complex microporous osmotic pump tablet shows zero order release and complete release within 12 h(cumulative release rate > 90%), indicating the possibility of reducing drug damage to the gastric mucosa. [ABSTRACT FROM AUTHOR]

摘要： 自发性脑出血是全球范围内致死致残的重要疾病之一，尽管其外科手术治疗已日趋成熟，但相应的术后管理方案尚不明晰。其中，脑出血术后存活患者发生主要心脑及外周血管事件的风险显著增加，但现行指南尚未明确能否以及何时启动抗血小板治疗。近期发表的自发性脑出血患者神经外科手术后早期抗血小板治疗（early-start antiplatelet treatment after neurosurgery in patients with spontaneous intracerebral hemorrhage，E-start）研究表明，对于具有高缺血事件风险的脑出血患者，术后早期启动抗血小板治疗可带来显著获益，且不增加出血风险。作为国内首个脑出血围手术期管理的高级别循证证据，E-start研究有助于提高脑出血救治与管理水平，改善患者预后。 Abstract: Spontaneous intracerebral hemorrhage is one of the important diseases causing death and disability worldwide. Although surgical treatment has become increasingly mature, the corresponding postoperative management strategies remain poorly defined. In this context, patients who survive after intracerebral hemorrhage surgery have a significantly increased risk of major cardiovascular, cerebrovascular, and peripheral vascular events. However, current guidelines have not yet established clear recommendations on whether or when to initiate antiplatelet therapy. The recently published early-start antiplatelet treatment after neurosurgery in patients with spontaneous intracerebral hemorrhage (E-start) study indicates that for intracerebral hemorrhage patients with a high risk of ischemic events, early initiation of postoperative antiplatelet therapy can bring significant benefits without increasing the risk of bleeding. As the first high-level evidence-based evidence on perioperative management of intracerebral hemorrhage in China, the E-start study is instrumental in improving the treatment and management standards for intracerebral hemorrhage and enhancing patient outcomes.

本文介绍了1例基于基因检测的后循环缺血介入治疗后抗血小板治疗的患者情况。该例患者为老年女性，基底动脉中段闭塞所致急性缺血性卒中，发病3 h内入院，给予静脉溶栓后桥接介入治疗，治疗后恢复较好（NIHSS评分从入院时的11分降至出院时的2分）。为个体化选择患者的抗血小板治疗方案，在介入治疗后进行细胞色素P450酶家族2亚家族C成员19（cytochrome P450 family 2 subfamily C member 19，CYP2C19）基因检测，显示为中间代谢型，提示患者可能存在氯吡格雷抵抗，选择替格瑞洛联合阿司匹林双联抗血小板方案进行3个月的抗血小板治疗，之后根据患者随访情况调整用药。出院后2个月随访时患者预后良好且未出现出血表现。 Abstract: This article described a case of a patient with antiplatelet therapy after interventional therapy for posterior circulation ischemia based on gene detection. The patient was an elderly female with acute ischemic stroke caused by middle segment occlusion of the basilar artery. She was admitted within 3 hours of onset and received intravenous thrombolysis followed by bridging interventional therapy. After treatment, the patient recovered well (NIHSS score decreased from 11 points at admission to 2 points at discharge). In order to individualize the selection of the patient’s antiplatelet therapy regimen, cytochrome P450 family 2 subfamily C member 19 (CYP2C19) gene detection was performed after interventional therapy, which showed an intermediate metabolism type, indicating that the patient may have clopidogrel resistance. Therefore, the dual antiplatelet therapy regimen of ticagrelor combined with aspirin was selected for 3 months for antiplatelet therapy, and then the medication was adjusted according to the patient’s follow-up. At two months of follow-up after discharge, the prognosis was good and there were no bleeding manifestations.

本文报道了一例老年女性院内卒中患者的临床诊疗过程。该患者于肛肠外科手术后2 d突发急性缺血性卒中，经影像学检查确诊为右侧颈内动脉起始部重度狭窄。在接受了1个月的卒中二级预防药物治疗后，择期行血管内治疗。术前该患者进行了快速细胞色素P450酶家族2亚家族C成员19（cytochrome P450 family 2 subfamily C member 19，CYP2C19）基因检测，结果为中间代谢型，提示应用氯吡格雷的效果可能不佳。基于这一检测结果调整抗血小板治疗方案，选择替格瑞洛联合阿司匹林作为替代治疗。治疗后，患者病情稳定，预后较好。本病例报道提示，在非轻型卒中患者中，快速CYP2C19基因检测可帮助选择抗血小板治疗策略，改善患者预后。 Abstract: This paper reported the clinical diagnosis and treatment process of an elderly female patient with in-hospital stroke. The patient suddenly developed acute ischemic stroke 2 days after an anorectal surgery and was diagnosed with severe stenosis at the origin of the right internal carotid artery by imaging examination. After one month of treatment with secondary prevention drugs for stroke, selective endovascular treatment was performed. The rapid detection of cytochrome P450 family 2 subfamily C member 19 (CYP2C19) gene before the operation showed that it was an intermediate metabolic type, suggesting that the effect of clopidogrel may be poor. Based on this result, the antiplatelet therapy regimen was adjusted and ticagrelor combined with aspirin was selected as a replacement therapy. After treatment, the patient’s condition was stable and the prognosis was good. This report suggests that rapid detection of the CYP2C19 gene can also be used to guide the selection of antiplatelet therapy strategies and improve outcomes in non-mild stroke patients.

Copyright of Chinese Journal of Stroke is the property of Chinese Journal of Stroke Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Stroke is the property of Chinese Journal of Stroke Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Stroke is the property of Chinese Journal of Stroke Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

目的 分析术前给予阿司匹林联合氯吡格雷双联抗血小板治疗的急性Stanford A型主动脉夹层手术患者 的预后, 以探讨术前双联抗血小板治疗对急性Stanford A型主动脉夹层手术患者预后的影响. 方法　回顾性分析中 山市人民医院 2017 年 8 月—2023 年 10 月接受手术治疗的 269 例 Stanford A 型主动脉夹层患者的预后相关临床资 料, 包括住院病死率, 术后并发症, 手术体循环及阻断时间等. 根据术前是否接受阿司匹林联合氯吡格雷双联抗血 小板治疗将患者分为双抗组30例和非抗组239例. 比较两组患者住院病死率, 术后并发症, 体循环时间, 并对住院 死亡危险因素进行 Logistic 回归分析. 结果　双抗组住院病死率高于非抗组 (P<0. 05) . 术前双联抗血小板治疗, 延长的体循时间以及术前冠状动脉造影检查是死亡的独立危险因素 (P均<0. 05) . 结论 与术前未接受双联抗血 小板治疗比较, 术前接受双联抗血小板治疗的急性Stanford A型主动脉夹层手术患者预后差; 双联抗血小板治疗是 急性Stanford A型主动脉夹层手术患者住院死亡的独立危险因素. [ABSTRACT FROM AUTHOR]

Since its advent, aspirin has garnered wide attention. With modern medical research and trials focusing on its chemical properties and clinical mechanisms, the scope of its clinical applications has been continuously expanded. This paper, written from a first-person perspective and in the form of a novel, introduces the history, mechanism of action, and modern research developments of aspirin. Additionally, it provides an outlook on its future development to offer readers a deeper understanding of its applications. [ABSTRACT FROM AUTHOR]

Objective To investigate the probability and influencing factors of gastrointestinal bleeding in acute myocardial infarction(AMI) patients with dual antiplatelet therapy with aspirin and ticagrelor after percutaneous coronary intervention (PCI). Methods We selected 1 200 patients who had undergone PCI due to AMI, and had received dual antiplatelet therapy with aspirin and ticagrelor after PCI. They were divided into bleeding group and non-bleeding group according to the presence or absence of gastrointestinal bleeding. The clinical data were compared between the two groups. The risk factors of gastrointestinal bleeding after PCI in AMI patients were analyzed by univariate and binary multivariate Logistic analysis. Results Among the 1 200 AMI patients treated by PCI, gastrointestinal bleeding occurred in 38 cases with an incidence rate of 3. 17%. Univariate analysis results showed that creatinine, age, and the proportion of patients with history of peptic ulcer and smoking history in the bleeding group were all significantly higher than those in the non-bleeding group, while hemoglobin and the proportion of patients taking proton pump inhibitors were significantly lower than those in the non-bleeding group (all P<0. 05). Binary multivariate Logistic regression analysis showed that age, smoking history, use of proton pump inhibitors, and hemoglobin were all independent influencing factors for gastrointestinal bleeding after PCI in AMI patients with dual antiplatelet therapy with aspirin and ticagrelor (all P<0. 01). Conclusion There is a high probability of gastrointestinal bleeding in AMI patients with dual antiplatelet therapy with aspirin and ticagrelor after PCI. Gastrointestinal bleeding could be influenced by various factors among these patients, and corresponding countermeasures should be formulated clinically, in order to reduce the occurrence of gastrointestinal bleeding and improve the prognosis of AMI patients. [ABSTRACT FROM AUTHOR]

OBJECTIVE: To explore the quality of clinical practice guidelines related to application of aspirin in preventing preeclampsia during pregnancy at home and abroad. METHODS: Clinical practice guidelines related to application of aspirin in preventing preeclampsia during pregnancy published from 2012 to 2023 were systematically retrieved, the Appraisal of Guidelines for Research and Evaluation Ⅱ (AGREE Ⅱ) were used to perform evaluation and analysis on the quality of enrolled guidelines, and to conduct comparison and summary on the main recommendations in each guidelines. RESULTS: A total of 18 clinical practice guidelines related to application of aspirin in preventing preeclampsia during pregnancy were enrolled, 4 of which were A-level recommendation, 13 were B-level recommendation and 1 was C-level recommendation. Results of general guideline evaluation based on AGREE Ⅱ indicated that the average scores were respectively 62. 96%, 60. 03%, 62. 21%, 96. 14%, 43. 06%, 66. 20% in the fields of range and purpose, participants, preciseness, explicitness, applicability, independence. Currently, the preventive application of aspirin for pregnant women with certain risk of preeclampsia were recommended in guidelines of various countries, while there were differences in the recommended treatment course and dosage of aspirin. CONCLUSIONS: Among the guidelines on aspirin for the prevention of preeclampsia published globally in the last 10 years, there are a relatively large number of moderate-quality and high-quality guidelines, with the main shortcomings centered in the applicability filed, as well as in items such as target population perspectives, selection criteria of evidence and involvement of external reviewers, which require further improvement by guideline developers [ABSTRACT FROM AUTHOR]

Objective: To explore the effect of intravenous immunoglobulin combined with aspirin drugs on the levels of lymphocyte subsets and related factors in children with Kawasaki disease. Methods: 105 children with Kawasaki disease admitted from March 2023 to February 2024 were selected and divided into 45 children in the control group with aspirin alone, and 60 children in the observation group were treated with intravenous immunoglobulin combined with aspirin. Compare the two groups of related indicators. Results: The total response rate was significantly higher than the observation group (P < 0.05) the values of CD4+, CD3+, CD4+ and CD4+/ CD8+ increased in the observation group (P < 0.05) IFN-γ, TNF-α, IL-2, IL-4, were lower than the observation group (P < 0.05) the incidence of adverse reactions between the two groups (P > 0.05) Conclusion: Intravenous immunoglobulin combined with aspirin in the treatment of Kawasaki disease has a remarkable effect, which can improve the level of lymphocyte subsets and related factors, then improve immune function, reduce inflammatory response, and have high safety. [ABSTRACT FROM AUTHOR]

Pre-eclampsia is a leading cause of maternal and newborn mortality worldwide, impacting long-term health outcomes for both mother and child. We describe and analyze the limitations and controversies related to using aspirin for preeclampsia prevention, and explore the involvement of other medications in preventative strategies. Furthermore, this article examines the pre-eclampsia prediction scheme for both singleton and twin pregnancies, emphasizing the importance of tertiary referral systems in the prevention and treatment of pre-eclampsia, aiming to further promoting high -quality pre -eclampsia prevention and treatment and improve maternal and child health in China. [ABSTRACT FROM AUTHOR]

Obstetric antiphospholipid syndrome (OAPS) is an autoimmune disease characterized by persistent positivity of antiphospholipid antibody (aPL) and pathological pregnancy, with clinical manifestations such as recurrent spontaneous abortion, fetal death, fetal growth restriction, preeclampsia, and premature delivery. Early diagnosis and appropriate management of the patients with OAPS can significantly reduce the incidence of pregnancy complications. Currently, the first-line therapeutic option is aspirin combined with low molecular weight heparin, which improves the pregnancy outcome in most patients. The second-line therapeutic medications, such as hydroxychloroquine and glucocorticoid, can be used as a complement to the first-line therapeutic option. The emerging therapeutic medications, such as biologics and statins, are still at the exploratory stage of clinical application. In this article, we review the advances in the diagnosis and treatment of OAPS. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Clinical Healthcare is the property of Chinese Journal of Clinical Healthcare and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Pharmacy & Clinical Remedies is the property of Editorial Department of Practical Pharmacy & Clinical Remedies and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

内囊预警综合征（capsule warning syndrome，CWS）是一组罕见的临床症状，具有反复发作刻板样神经功能缺损症状，易进展成完全性卒中的特点。本研究报道1例表现为发作性言语不清伴左侧肢体无力的CWS，该患者经阿替普酶静脉溶栓治疗后24 h内，仍反复发作刻板样言语不清、左侧肢体无力。经评估风险后，静脉溶栓后24 h内予以替罗非班抗血小板聚集治疗，3 d后桥接双重抗血小板聚集治疗，患者未再发作神经功能缺损症状。静脉溶栓治疗后启动抗血小板聚集时机以及抗血小板聚集的方案，仍需大规模数据进一步探讨。 Abstract: Capsule warning syndrome (CWS) is a group of rare clinical symptoms with frequent episodes of stereotyped neurological deficits, and easy progression to complete stroke. This study reported a case of CWS with paroxysmal speech inarticulateness and left limb weakness. Within 24 hours after intravenous thrombolysis with alteplase, the patient still had repeated episodes of stereotypical speech inarticulateness and left limb weakness. After assessing the risk, tirofiban was given within 24 hours after intravenous thrombolysis, and dual antiplatelet therapy was bridged 3 days later. The patient had no recurrence of neurological deficits. However, the timing of initiation of dual antiplatelet therapy after intravenous thrombolysis and the dual antiplatelet therapy program still need large-scale data to further explore.

Copyright of Chinese Journal of Stroke is the property of Chinese Journal of Stroke Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Taking the organic chemistry experiment “Synthesis of Aspirin” as an example, this paper discusses the specific implementation measures of integrating ideological and political education into the organic chemistry laboratory course through five steps: determining ideological and political teaching objectives, mining ideological and political elements, selecting ideological and political carriers, conducting ideological and political practice activities, and conducting ideological and political evaluation. Adopting a progressive teaching model, this paper proposes several suggestions and measures for the effective implementation of ideological and political education in laboratory courses. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Clinical Healthcare is the property of Chinese Journal of Clinical Healthcare and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective To investigate the effect of aspirin in relieving skin rashes induced by epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in mice and the possible mechanism. Methods Fifty male Balb/c mice were randomly divided into the control group, model group, and high-dose, medium-dose, and low-dose aspirin groups, with 10 mice in each group. The skin rash models were established by administering the EGFR-TKI erlotinib to the mice in all the groups except the control group. After successful modeling, the mice in the high-, medium-, and low-dose aspirin groups were given aspirin at doses of 1. 13, 0. 75, and 0. 38 mg per mouse, respectively, while the mice in the control group were given distilled water at 100 mg/kg, all by gavage, once a day, for a total of 30 days. All the mice were monitored for feeding, drinking, urination, defecation, and mental status as well as pruritus and other skin conditions. The skin moisture level was measured using a skin moisture analyzer, and skin inflammation was scored. After the mice were sacrificed, the back skin was taken for observing the pathological changes with HE staining, and serum levels of tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) were determined by ELISA. Results In the control group, the skin and general conditions were normal; the mice in the model and low-dose aspirin groups developed skin rashes, scabs, and desquamation on the back, and began to have reduced food intake, increased water intake, increased urination, and reduced defecation since the first week, accompanied by anxiety and back scratching; compared with the model group, the medium- and high-dose aspirin groups showed significant improvements in skin rashes, scabs, and desquamation, and gradually returned to normal dieting since the second week. Only the model group had mild pruritus, while the other groups did not have any pruritus. No abnormal changes were found in any epidermal layer of the skin tissues in the control group; the model group showed epidermal thickening and substantial inflammatory cell infiltration in the dermis; the high dose and medium-dose aspirin groups showed slight epidermal thickening and mild inflammatory cell infiltration in the superficial dermis, while the low-dose aspirin group had a larger number of inflammatory cells in the superficial dermis; the levels of inflammation in the three aspirin groups were all lower than that in the model group. There was no significant difference in the skin moisture level between the groups (P<0. 05). The rash site, desquamation, exudation, skin thickening score, and serum levels of TNF-α and IL-1β were as follows： the control group < the high-dose aspirin group < the medium dose aspirin group < the low-dose aspirin group and model group (all P<0. 05). Conclusion Aspirin can alleviate EGFR-TKI-induced skin rashes in mice, possibly through reducing serum TNF-α and IL-1β levels and thereby inhibiting inflammatory response. [ABSTRACT FROM AUTHOR]

临床试验是评估新药或新疗法有效性和安全性最有效的方法，可以提供高质量的循证医学证据。近年来全球的临床试验数量逐渐增加，试验结果为阴性十分常见。当临床试验的主要结果为阴性时，并不一定就意味着研究的失败，研究者还需要多方考虑以便从中找到潜在益处的线索。本文阐述了临床试验主要结局为阴性时需要考虑的12个要点，并以吲哚布芬对比阿司匹林治疗急性缺血性卒中（indobufen versus aspirin in acute ischemic stroke，INSURE）研究为例进行讨论，以期为后续的临床试验设计和结果解读提供经验。 Abstract: Clinical trials are the most effective method for evaluating the efficacy and safety of new drugs or new therapies, and can provide high-quality evidence-based medical evidence. In recent years, the number of clinical trials worldwide increased gradually, negative results from clinical trials are very common. When the main result of a clinical trial is negative, it does not necessarily mean that the study is a failure, and researchers should consider multiple factors to find potential benefits. Therefore, we elaborated in detail the 12 key points to consider, when encountering the negative primary outcome, and discussed by taking indobufen versus aspirin in acute ischemic stroke (INSURE) study as an example provide reference experience for subsequent clinical research design and results interpretation.

BACKGROUND: Aspirin is a classic non-steroidal anti-inflammatory drug. Appropriate doses of aspirin can regulate immunity and promote osteogenesis. The preparation of bone tissue engineering materials, which can release aspirin, regulate the immune microenvironment of the bone defect area and accelerate the repair of the bone defect, and is a current research focus. OBJECTIVE: To prepare a novel hydrogel scaffold that can modulate the immune microenvironment and quickly repair the bone defect area. METHODS: Hydrogel scaffolds containing 0%, 10% and 20% of nano-hydroxyapatite/aspirin/polyvinyl alcohol/gelatin/sodium alginate were prepared. The microstructure, porosity, chemical composition, crystal structure, drug release properties, mechanical properties, swelling properties and degradation properties of the hydrogel scaffolds were characterized. The biocompatibility of the hydrogel scaffolds was evaluated by cell proliferation and cytotoxicity experiments. RESULTS AND CONCLUSION: (1) Scanning electron microscope and porosity results showed that hydrogel scaffolds in the 0% nano-hydroxyapatite group and 10% nano-hydroxyapatite group had better biomimetic hierarchical porous structure, pore connectivity, and porosity. (2) The results of Fourier transform infrared spectroscopy and X-ray diffraction showed that the raw materials in the hydrogel scaffold were combined by physical and chemical double crosslinking, and the crystal phase structure of nano-hydroxyapatite was not be destroyed. (3) The results of mechanical properties showed that the 10% nanohydroxyapatite group had the best compressive modulus and compressive strength. (4) The results of drug release properties showed that the cumulative release rate of aspirin decreased with the increase of nano-hydroxyapatite, but the drug burst release rate decreased and the sustained release time prolonged. (5) The results of swelling properties and degradation properties showed that with the increase of nano-hydroxyapatite, the swelling rate and degradation rate of hydrogel scaffolds of each group decreased. (6) Using the hydrogel scaffold extract to culture mouse pre-osteoblasts, the results of cell proliferation and cytotoxicity experiments showed that the hydrogel scaffold extract could promote cell proliferation, without cytotoxicity. (7) It is concluded that 10% nanohydroxyapatite hydrogel scaffolds have better bionic characterization and biocompatibility, and are expected to be used as bone tissue engineering scaffolds for further studies of osteogenesis and immunomodulatory potential. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Shenyang Pharmaceutical University is the property of Shenyang Pharmaceutical University and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

OBJECTIVE: To probe into the clinical efficacy of Shenrong Baotai pills combined with conventional western medicine (dydrogesterone + aspirin) in patients with recurrent spontaneous abortion (RSA) complicated with prethrombotic state ( PTS) and its effects on levels of coagulation and fibrinolysis system and serum inflammatory factors. METHODS: Totally 96 patients with RSA complicated with PTS admitted into the hospital from Jan. 2015 to May 2021 were extracted to be divided into two groups via the random number table method. The control group was given dydrogestrel and aspirin, while the observation group received Shenrong Baotai pills on the basis of the control group. The clinical efficacy of two groups was observed by continuous medication for 12 weeks of gestation. Coagulation and fibrinolysis indexes [activated partial thrombin time (APTT), thrombin time (TT), prothrombin time (PT), antithrombin Ⅲ (AT-Ⅲ) activity, protein C ( PC) activity, protein S ( PS) activity, fibrinogen ( FIB), D-dimer (D-D)], and levels of tumor necrosis factor α ( TNF-α), interleukin ( IL) 1β, and IL-17 in both groups were detected before and after treatment. Adverse drug reactions of two groups were recorded. Follow-up until the end of pregnancy, and pregnancy outcomes were counted in both groups. RESULTS: The total effective rate of the observation group was 97. 92% ( 47 / 48), significantly higher than 87. 50% ( 42 / 48) of the control group, the difference was statistically significant (P<0. 05). APTT, TT and PT in both groups were significantly prolonged after treatment compared with before treatment ( P < 0. 05), the activities of AT-Ⅲ, PC and PS increased significantly compared with before treatment (P < 0. 05), and the levels of FIB and D-D decreased significantly compared with before treatment (P<0. 05); after treatment, APTT, TT and PT in the observation group were significantly longer than those in the control group (P<0. 05), the activities of AT-Ⅲ, PC and PS were significantly higher than those in the control group (P<0. 05), and the levels of FIB and D-D were significantly lower than those in the control group (P< 0. 05), with statistically significant differences. Serum levels of TNF-α, IL-1β and IL-17 in both groups decreased significantly after treatment compared with those before treatment, and the reduction was more significant in the observation group, with statistically significant differences (P<0. 05). The live birth rate in the observation group was 89. 58% (43 / 48), significantly higher than 72. 92% ( 35 / 48) in the control group, with statistically significant differences (P < 0. 05). The incidence of adverse drug reactions in the observation group was 6. 25% ( 3 / 48), compared with 4. 17% ( 2 / 48) in the control group, the difference was not statistically significant ( P > 0. 05). CONCLUSIONS: Shenrong Baotai pills combined with conventional western medicine (dydrogesterone + aspirin) can safely and effectively regulate the imbalance of coagulation and fibrinolysis system in patients with RSA complicated with PTS, down-regulate the expressions of TNF-α, IL-1β and IL-17, improve the clinical efficacy and pregnancy outcome. [ABSTRACT FROM AUTHOR]

Objective To investigate the preventive effect of aspirin on cerebral infarction after vascular bypass grafting in moyamoya disease（MMD）. Methods Clinical data of 565 patients with MMD who received vascular bypass grafts in the Department of Neurosurgery, the First Affiliated Hospital of Nanchang University from January 2014 to October 2019 were analyzed retrospectively. They were divided into aspirin group（406 cases） and non-aspirin group（159 cases, control group） according to whether aspirin was used after surgery. In order to clarify the role of aspirin in the occurrence of cerebral infarction after MMD, the incidence of cerebral infarction during perioperative period and cerebral hemorrhage within 3 months after surgery in the two groups was statistically analyzed. Neurological function at admission, discharge, and 3 months after surgery was assessed by using modified Rankin scale（mRS） score. Results Among the 565 patients, 26 were diagnosed with postoperative cerebral infarction. The incidence of perioperative cerebral infarction was 3.2%（13/406） in the aspirin group,and the incidence of cerebral hemorrhage was 1. 2%（ 5/406） within 3months after surgery. In the control group,the incidence of cerebral infarction in the perioperative period was 8. 2%（ 13/159）,and the incidence of cerebral hemorrhage in the 3 months after surgery was 0. 6%（ 1/159）. There were no significant differences in gender,age and history of hypertension between 2 groups（ all P ＞ 0. 05）. There were statistically significance in perioperative cerebral infarction,transient ischemic attack,mRS Score at discharge and neurological deterioration at discharge between the two groups（ all P ＜ 0. 05）. There were no significant differences in cerebral hemorrhage 3 months after surgery,mRS score 3 months after surgery and neurological function 3months after surgery between the two groups（ all P ＞ 0. 05）. Univariate analysis showed that patients’ age,history of hypertension and diabetes,and posterior cerebral artery stenosis or occlusion were possible influencing factors for cerebral infarction after MMD（ all P ＜ 0. 05）. Multivariate Logistic regression analysis showed that history of hypertension（ OR = 0. 204,95% CI: 0. 067-0. 623,P = 0. 005）,infarct MMD（ OR = 0. 084,95% CI: 0. 025-0. 277,P ＜ 0. 001）,left vascular bypass（ OR = 0. 234,95% CI: 0. 076-0. 720,P = 0. 011）,posterior cerebral artery stenosis OR occlusion（ OR = 0. 008,95% CI: 0. 002-0. 037,P ＜ 0. 001） was a risk factor for cerebral infarction after MMD,and postoperative aspirin（ OR = 2. 897,95% CI: 1. 024-8. 197,P = 0. 045） was a protective factor for preventing cerebral infarction after MMD. Conclusion Routine use of aspirin after vascular bypass surgery can reduce the incidence of acute cerebral infarction in patients with MMD. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Stroke is the property of Chinese Journal of Stroke Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To explore the mechanism of aspirin inhibiting intracranial aneurysm formation in rats by regulating Hippo pathway. Methods: Forty healthy SD rats were selected and divided into control group (without any treatment), sham operation group (exposing the posterior branches of bilateral renal arteries and left common carotid artery, but without ligation), aneurysm group (perfusing normal saline after ligating the posterior branches of bilateral renal arteries and left common carotid artery) and aspirin group (perfusing aspirin after artery ligation), with 10 rats in each group. Detection of serum inflammatory factors [tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1), interleukin-6 (IL-6), IL-10)] and vascular endothelial injury markers [nitric oxide (NO), endothelin-1 (ET-1), vascular endothelial growth factor (VEGF)] 12 weeks after intragastric administration. After the rats were killed, the aneurysm size, wall thickness ratio, lumen area and thinning length of the middle membrane were detected. The expression of Yes-associated protein (YAP) was detected. Results: 1) There were obvious bulges on the Willis ring in the aneurysm group and aspirin group, and the bulges in the aspirin group were smaller than those in the aneurysm group. The aneurysm size, lumen area and thinning length of middle membrane in aspirin group were smaller than those in aneurysm group, and the wall thickness ratio was greater than that in aneurysm group (P<0.05). (2) The serum levels of TNF-α, MCP-1 and IL-6 of rats in aneurysm group and aspirin group were higher than those in the control group and sham operation group, while the levels of IL-10 were lower than those in the control group and sham operation group (P<0.05); The serum levels of TNF-α, MCP-1 and IL-6 of rats in aspirin group were lower than those in aneurysm group, while the levels of IL-10 were higher than those in aneurysm group (P<0.05). (3) The levels of serum NO, ET-1 and VEGF in aneurysm group and aspirin group were lower than those in control group and sham operation group (P<0.05); The level of serum NO in aspirin group was higher than that in aneurysm group, and the levels of ET-1 and VEGF were higher than that in aneurysm group (P<0.05). (4) The relative absorbance value of YAP protein expression in aneurysm group and aspirin group was significantly higher than that in control group and sham operation group (P<0.05). The relative light absorption value of YAP protein expression in aspirin group was lower than that in aneurysm group (P<0.05). Conclusion: Aspirin can significantly reduce the inflammatory reaction of rats with intracranial aneurysms, improve vascular endothelial function, and inhibit the formation of intracranial aneurysms, which may be related to the regulation of Hippo signal pathway by inhibiting YAP. [ABSTRACT FROM AUTHOR]

目的 探索阿司匹林和氯吡格雷联合应用对小鼠大脑中动脉远端缺血再灌注模型恢复期晚期糖基化终末产物受体（receptor for advanced glycation end products，RAGE）及可溶性晚期糖基化终末产物受体（soluble receptor for advanced glycation end products，sRAGE）表达的影响及其机制。 方法 60只C57BL/6J雄性小鼠随机分为假手术组、溶剂组、阿司匹林和氯吡格雷联合组（双抗组），每组20只。通过压迫大脑中动脉远端制作脑缺血再灌注模型（缺血60 min再灌注），再灌注即刻灌胃，溶剂组给予饮用水100 μL，双抗组给予阿司匹林（剂量12 mg/kg，每只实际用量0.3 mg）与氯吡格雷（剂量12 mg/kg，每只实际用量0.3 mg）混悬液100 μL，每日1次，连续21 d。缺血1、3、5、7、9、11、14、21 d对小鼠进行神经功能评价。缺血21 d取材，酶联免疫吸附法检测小鼠血清sRAGE表达水平；免疫印记检测脑组织RAGE表达水平；实时荧光定量PCR检测CD16、CD32、CD11b、诱导型一氧化氮合成酶（inducible nitric-oxide synthase，iNOS）、CD206、精氨酸酶1（arginase1，Arg1）、转化生长因子β（transforming growth factor β，TGF-β）、几丁质酶样蛋白（chitinase-like 3，Chil3/Ym1/2）等炎症因子及RAGE的mRNA表达情况；免疫荧光染色标记RAGE、神经元特异核蛋白（neuronal nuclei，NeuN）、胶质纤维酸性蛋白（glial fibrillary acidic protein，GFAP），观察RAGE与神经元和星形胶质细胞共定位情况。 结果 双抗组小鼠3 d时胡须碰触评分和神经功能总分、9 d时神经功能总分优于溶剂组，差异有统计学意义（P=0.0067、0.0140、0.0406）。缺血再灌注21 d时，双抗组小鼠血清sRAGE表达水平高于溶剂组（1.099±0.541 ng/mL vs. 0.319±0.341 ng/mL，P=0.0120）；脑组织iNOS（1.250±0.318 vs. 1.843±0.301，P=0.0164）及RAGE（2.105±0.300 vs. 2.732±0.249，P=0.0071）的mRNA相对表达较溶剂组下降。在小鼠脑梗死周边区RAGE与神经元具有共定位，与星形胶质细胞无共定位；双抗组RAGE+NeuN+细胞数量少于溶剂组（328.798±35.183个/平方毫米 vs. 814.437±165.758个/平方毫米，P=0.0012）。 结论 阿司匹林和氯吡格雷联合应用可能通过下调RAGE、上调sRAGE的表达水平，减轻炎症反应，从而发挥脑保护作用。 Abstract: Objective To explore the effects and mechanisms of aspirin combined with clopidogrel (ASA+CPG) on the expression of receptor for advanced glycation end products (RAGE) and soluble receptor for advanced glycation end products (sRAGE) in the convalescent stage of distal middle cerebral artery occlusion-reperfusion model in mice. Methods 60 male C57BL/6J mice were randomly divided into sham operation group, vehicle group and ASA+CPG group, 20 mice per group. A model of transient cerebral ischemia was performed by occluding the distal middle cerebral artery (ischemia for 60 minutes, then restore to reperfusion). 100 μL suspension of aspirin (12 mg/kg, 0.3 mg per mouse), clopidogrel (12 mg/kg, 0.3 mg per mouse) and water were administered by gavage at the onset of reperfusion, once a day for 21 days. The neurological function of mice was evaluated on day 1, 3, 5, 7, 9, 11, 14 and 21 after ischemia. Samples were harvested 21 days after ischemia. The serum sRAGE expression level was detected by enzyme-linked immunosorbent assay (ELISA). Immunoblotting was used to evaluate RAGE expression in brain tissues. Real-time quantitative PCR was applied to detect the mRNA expression levels of CD16, CD32, CD11b, inducible nitric oxide synthase (iNOS), CD206, arginase 1 (Arg1), transforming growth factor β (TGF-β), chitinase-like 3 (Chil3/Ym1/2) and RAGE. RAGE, neuronal nuclei (NeuN) and glial fibrillary acidic protein (GFAP) were labelled by immunofluence to observe the colocalization of RAGE with neurons and astrocytes. Results The vibrissae touch score at day 3, neurological function total score at day 3 and day 9 in ASA+CPG group were better than those in vehicle group (P=0.0067, 0.0140, 0.0406). At 21 days after ischemia, the level of serum sRAGE in ASA+CPG group was higher than that in vehicle group (1.099±0.541 ng/mL vs. 0.319±0.341 ng/mL, P=0.0120). The mRNA expression levels of iNOS (1.250±0.318 vs. 1.843±0.301, P=0.0164) and RAGE (2.105±0.300 vs. 2.732±0.249, P=0.0071) in ASA+CPG group decreased compared with vehicle group. RAGE colocalized with neurons but not with astrocytes in peri-infarct area of ischemic mice. The number of RAGE+NeuN+ cells in ASA+CPG group was less than that in vehicle group (328.798±35.183 vs. 814.437±165.758 per square millimeter, P=0.0012). Conclusions Combined treatment with aspirin and clopidogrel plays cerebral ischemia protective effect by down-regulate RAGE and up-regulate sRAGE expression to alleviate inflammatory response.

目的 探讨小鼠脑缺血损伤后阿司匹林和氯吡格雷联合应用21 d对骨髓中性粒细胞炎症因子及脑内小胶质细胞极化的影响。 方法 雄性C57BL/6小鼠随机分为对照组、阿司匹林联合氯吡格雷组（双抗组）2组，每组10只。通过结扎大脑中动脉远端制作脑缺血再灌注模型（缺血60 min，解开结扎实现再灌注），再灌注即刻通过灌胃给予饮用水100 μL（对照组）和阿司匹林（剂量12 mg/kg，每只实际用量0.3 mg）与氯吡格雷（剂量12 mg/kg，每只实际用量0.3 mg）混悬液100 μL（双抗组），每日1次，连续21 d。21 d后处死小鼠，分离骨髓中性粒细胞，通过实时荧光定量PCR检测骨髓中性粒细胞相关炎症因子，包括IL-1β、IL-6、IL-10、诱导型一氧化氮合酶（inducible nitric-oxide synthase，iNOS）、TNFα、精氨酸酶1（arginase1，Arg1）、转化生长因子β（transforming growth factor β，TGFβ）、CD206、CD32、几丁质酶样蛋白（chitinase-like3，Chil3/YM1）的表达情况。脑组织行冰冻切片，免疫荧光染色标记离子化钙结合适配分子1（ionizedcalcium binding adapter molecule 1，Iba1）、CD16和CD206，观察小胶质细胞数量、形态变化与极化状态。 结果 与对照组相比，治疗21 d后双抗组小鼠骨髓中性粒细胞IL-1β的相对表达下降（0.703±0.124vs. 1.000±0.203，P =0.019）；YM1（2.173±0.968 vs. 1.000±0.282，P =0.019）和CD206（1.361±0.203vs. 1.000±0.260，P =0.048）的相对表达上调。治疗21 d后双抗组与对照组梗死周边区的小胶质细胞数量差异无统计学意义，但双抗组CD16阳性（M1型）小胶质细胞数量降低（119.4±37.43个/平方毫米vs. 220.2±63.07个/平方毫米，P

Pre-eclampsia (PE), as a hypertensive disorder of pregnancy, seriously affects maternal and infant health and long-term quality of life. However, clinical intervention for PE is limited to passive management after the oneset of symptoms, which often leads to poor prognosis of mother and infant. Therefore, the research on pre -symptomatic prevention of PE has become a hot topic. Aspirin is currently the most widely used preventive drug for PE. However, with the deepening of the research on the etiology of PE, many drugs have been proved to be used to prevent PE. In recent years, in addition to aspirin, anticoagulants, antioxidants, pravastatin, metformin, oral microbiome and other drugs have made great progress in the prevention and treatment of PE. This article reviews the main drugs that can be used for the prevention and treatment of PE, in order to help the early prevention of PE in clinical practice. [ABSTRACT FROM AUTHOR]

OBJECTIVE: To probe into the effect of low-dose aspirin combined with labetalol and nifedipine on the efficacy in the treatment of pre-eclampsia. METHODS: Totally 254 patients with pre-eclampsia admitted into Huai’an Maternal and Child Health Hospital from Feb. 2021 to Dec. 2021 were prospectively selected and divided into control group and observation group by random number table method, with 127 patients in each group. The observation group was given Labetalol hydrochloride tablets combined with low-dose aspirin tablets, while the control group was given Nifedipine sustained-release tablets combined with low-dose aspirin tablets. The therapeutic effects, serum cystatin C (CysC), hemodynamic indexes (blood viscosity, hematocrit value, cardiac index), adverse pregnancy outcomes (intrauterine distress, neonatal asphyxia, uterine inertia, postpartum hemorrhage, cesarean section, premature infants), adverse drug reactions (nausea, vomiting, myasthenia, abdominal pain) were observed and compared between two groups before and after treatment. To compare and analyze the application value of aspirin combined with labetalol or nifedipine in the treatment of pre-eclampsia. RESULTS: Compared with the control group (88. 98%, 113/127), the total effective rate of the observation group (96. 85%, 123/127) was significantly higher, with statistically significant difference (P<0. 05). After treatment, the CysC level of the observation group lower than that of the control group, with statistically significant difference ( P < 0. 05). After treatment, the blood viscosity, hematocrit value and cardiac index of both groups had been improved than those before treatment; the blood viscosity and hematocrit value were lower, and the cardiac index was higher in the observation group than the control group, with statistically significant differences (P < 0. 05). Compared with the control group, the incidence of adverse pregnancy outcomes of the observation group (17. 32%, 22/127) was lower than that of the control group (28. 35%, 36/127), the incidence of adverse drug reactions of the observation group (2. 36%, 3/127) was lower than that of the control group (11. 02%, 14/127), with statistically significant differences (P<0. 05). CONCLUSIONS: Compared with low-dose aspirin combined with nifedipine, low-dose aspirin combined with labetalol has better efficacy in the treatment of pre-eclampsia, with more significant improvements in renal function and hemodynamics and a lower probability of adverse pregnancy outcomes in patients, without increased adverse drug reactions. [ABSTRACT FROM AUTHOR]

BACKGROUND: Titanium as a bone substitute material has been widely used in the field of oral implant devices, but its bioinert would affect the stable combination with bone tissue at the early stage of implantation. Therefore, exploring to improve the osteogenic properties of titanium through surface modification is necessary. OBJECTIVE: To investigate the effect of composite coating of aspirin loaded chitosan nanoparticles and polydopamine on the viability of osteoblasts in vitro. METHODS: The titanium sheets modified by polydopamine coating as well as aspirin loaded chitosan nanoparticles and polydopamine composite coating were constructed. The surface morphology and microstructure of the coatings were characterized by scanning electron microscopy. In vitro sustained-release properties of aspirin nanosphere coatings on pure titanium were detected. Rat bone marrow mesenchymal stem cells were seeded and cultured on the pure titanium sheet and the two kinds of modified titanium sheets. The spreading morphology of rat bone marrow mesenchymal stem cells on the surface of titanium sheets was observed by cytoskeleton staining. Cell proliferation was determined by CCK-8 assay. The osteogenic differentiation of rat bone marrow mesenchymal stem cells on titanium sheets was measured using alkaline phosphatase staining and immunofluorescence staining. RESULTS AND CONCLUSION: (1) Scanning electron microscope images showed that the pure titanium surface was relatively smooth, and deposits as well as grain appeared after the dopamine polymerization. Aspirin microspheres were spherical with uniform size distribution. The hydrophilicity of the nanoparticles immobilized titanium surfaces and the polydopamine coating modified titanium surfaces were better than that of the pure titanium sheets (P < 0.05). The aspirin appeared to be slow and sustained under the encapsulation of chitosan nanoparticles. (2) As observed by cytoskeleton staining, the cells showed insufficient cell expansion on the surface of the pure titanium sheets and formed a few filopodia on the dopamine modified titanium sheets. The cells on nanoparticles modified sheets showed perfect expansion. (3) CCK-8 assay showed that the titanium sheets had no obvious cytotoxicity, and the cell proliferation rate of the nanoparticles modified titanium sheets displayed higher rates of proliferation than that of the dopamine coated and pure titanium sheets with increasing cell culture time (P < 0.05). (4) Alkaline phosphatase activity was highest on the surfaces of nanoparticles modified sheets. Immunofluorescence showed that the fluorescence intensity of alkaline phosphatase was strongest. (5) The results showed that the sustained-release coating of aspirin loaded chitosan nanoparticles on the titanium surfaces could enhance the proliferation and adhesion of rat bone marrow mesenchymal stem cells and promote osteogenic differentiation. [ABSTRACT FROM AUTHOR]

Copyright of Experimental Technology & Management is the property of Experimental Technology & Management Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective To investigate the diagnostic value of serum pepsinogen I(PGI), pepsinogen II(PGII), gastrin 17(G-17), and homocysteine(Hcy)levels in the diagnosis of peptic ulcer bleeding(PUB)in patients with coronary artery disease who take aspirin for a long time(continuous use for >3 months). Methods One hundred and two patients with coronary artery disease requiring long-term aspirin were selected and were divided into the PUB group of 36 cases and the no-PUB group of 66 cases according to whether PUB occurred. The clinical data were collected, and the serum PGI, PGII, and G-17 were measured by fluorescence immunochromatography, and Hcy level was measured by circulating enzyme method. Multi-factor Logistic regression was used to analyze the influencing factors of PUB in patients with coronary heart disease who took aspirin for a long time. The diagnostic value of serum PGI and PGII, G-17 and Hcy levels on PUB in patients with coronary heart disease who took aspirin for a long time was analyzed by using receiver operating characteristic(ROC)curves. Results The PUB group was older than the no-PUB group, and the PUB group had higher BMI, proportion of hypertension, proportion of history of gastrointestinal disease and serum PGI, PGII, G-17 and Hcy levels than the no-PUB group, and had longer aspirin use time(all P<0. 05). Multifactorial Logistic regression analysis showed that increasing age(OR = 1. 365, 95% CI: 1. 011 to 1. 843), history of GI disease(OR = 1. 095, 95% CI: 1. 015 to 1. 182), elevated PGI(OR = 1. 076, 95% CI: 1. 016 to 1. 140), elevated PG II(OR = 1. 097, 95% CI: 1. 027 to 1. 171), elevated G-17(OR = 1. 072, 95% CI: 1. 025 to 1. 120), and elevated Hcy levels(OR = 1. 215, 95% CI: 1. 050 to 1. 406) were independent risk factors for PUB in patients with coronary artery disease who took aspirin for a long time(all P<0. 05). ROC curve analysis showed that the area under the ROC curve(AUC)of serum PGI, PGII, G-17, and Hcy levels, and their combination in diagnosis of PUB in patients who took long-term aspirin for coronary artery disease was 0. 686, 0. 689, 0. 682, 0. 738, and 0. 885, respectively, and the AUC of their combined diagnosis was greater than that of separate diagnosis alone(P<0. 05). Conclusion Elevated serum PGI, PGII, G-17 and Hcy levels are independent risk factors for PUB in patients with coronary artery disease who take aspirin for a long time, and the combination of PGI, PGII, G-17 and Hcy is of high value in the diagnosis of PUB. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Contemporary Pediatrics is the property of Xiangya Medical Periodical Press and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To investigate the effect of butylphthalide on the expression of synaptophysin and postsynaptic density (PSD)-95 in serum and brain tissue of rats with cerebral infarction. Methods: The successfully modeled rats of cerebral infarction were equally randomly divided into three groups-butylphthalide group, aspirin group and model group. The three groups were given intraperitoneal injection of butylphthalide injection 20 mg/kg+ aspirin 20 mg/kg, aspirin 20 mg/kg and equal volume of saline, once daily, and the changes in the expression of synaptophysin and PSD-95 in serum and brain tissue were detected. Results: (1) On the 7th day and the 14th day after treatment, the m NSS of the rats in the butylphthalide group and the aspirin group were significantly lower than those in the model group (P<0. 05), and the butylphthalide group was lower than the aspirin group (P<0. 05); (2) On the 7th day and the 14th day after treatment, the percentage of cerebral infarction volume of rats in the butylphthalide group and the aspirin group was significantly lower than that of the model group (P<0. 05), and the butylphthalide group was lower than the aspirin group (P<0. 05); (3) On the 7th day of treatment and the 14th day of treatment, the expression levels of serum synaptophysin and PSD-95 in the butylphthalide group and aspirin group were significantly higher than those in the model group (P<0. 05), and the butylphthalide group was higher than the aspirin group (P<0. 05); (4) The relative expression levels of synaptophysin and PSD-95 protein in the brain tissue of the rats in the butylphthalide group and the aspirin group were significantly higher than those in the model group on the 7th day and the 14th day after treatment (P<0. 05), and the butylphthalide group was higher than the aspirin group (P<0. 05). Conclusion: The application of butylphthalide in cerebral infarction model rats can promote the expression of synaptophysin and PSD-95 in rat serum and brain tissue, and reduce the area of cerebral infarction, which is conducive to the recovery of neurological function in rats. [ABSTRACT FROM AUTHOR]

目的：观察氯吡格雷联合阿司匹林急诊治疗急性心肌梗死的临床效果。方法：选取2020年1月—2021年2 月梓潼县人民医院收治的急性心肌梗死患者80例进行对比研究, 借助速记数字表法进行分组, 其中联合用药组与单一 用药组各40例, 联合用药组采用氯吡格雷联合阿司匹林治疗, 单一用药组采用阿司匹林治疗, 比较2组患者的治疗效 果、治疗前后凝血因子指标水平及不良反应。结果：联合用药组患者总有效率为95.00%, 高于单一用药组的75.00% (χ2 = 6.275, P = 0.012)；治疗后, 2组患者的部分凝血酶原时间 (PT)和活化部分凝血酶时间 (APTT)均较治疗前 延长, 且联合用药组长于单一用药组 (P < 0.05)；联合用药组患者心绞痛和心源性死亡的发生率均低于单一用药组 (P < 0.05)；单一用药组与联合用药组患者血尿和心肌梗死复发的发生率比较差异不显著 (P > 0.05)。结论：氯吡 格雷联合阿司匹林治疗急性心肌梗死的疗效优于阿司匹林单药治疗, 且可有效改善患者的凝血因子水平, 加快患者恢 复, 还可降低心血管事件的发生风险, 药物安全性较高, 值得临床应用。 [ABSTRACT FROM AUTHOR]

Copyright of Transactions of China Pulp & Paper is the property of China Pulp & Paper Magazines Publisher and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective To analyze the effect of aspirin on gastric mucosal secretion function, bleeding, atrophy and cancer risk in patients with chronic atrophic gastritis (CAG). Methods A total of 97 patients with CAG confirmed by gastroscopy in this hospital from August 2019 to February 2020 were randomly divided into two groups. Helicobacter pylori(HP)antibody (+) was treated. The treatment group(48 cases) was treated with aspirin 100 mg/d for one year, while the control group(49 cases)had non NSAIDs. After 3,9 months of follow-up, the serum gastric function indexes including pepsinogen Ⅰ(PGⅠ), pepsinogen Ⅱ (PGⅡ), gastric secrete element - 17(G-17) and HP antibody were detected. The high-risk population were examined by endoscopy according to the new gastric cancer screening scoring system. SPSS20.0 was used to analyze the effect of aspirin on the above indicators, and to assess the risk of bleeding and cancer. Results Among the 97 CAG patients, there were 74 cases of closed type(type C), of which type C-1 accounted for 48.6%, type C-2 for 33.8%, and type C-3 for 17.6%;while open type(type O) had 23 cases, type O-1 accounted for 65.2%, type O-2 for 21.7%, type O-3 for 13.0%. There was no significant difference in the bleeding rate between the control and treatment group [6.12%(3/49) and 8.33%(4/48)](P >0.05). In the treatment group, the serum PGⅠ level and PGⅠ/PGⅡ (PGR)increased significantly, and the serum G-17 level decreased, the differences were statistically significant(P <0.05). After radical cure of HP, the new gastric cancer screening score in both groups decreased, especially in the treatment group, the differences were statistically significant(P < 0.05). Conclusion Aspirin reduces the risk of gastrointestinal cancer in patients with CAG. [ABSTRACT FROM AUTHOR]

目的 观察替罗非班静注联合替格瑞洛、阿司匹林口服治疗急性非致残性缺血性脑卒中（ANIS）的临床 效果。方法 160例ANIS患者根据用药方案不同分为观察组和对照组各80例，观察组采用替罗非班静注联合替格 瑞洛、阿司匹林口服，对照组采用替格瑞洛、阿司匹林口服，比较两组治疗后 90 d主要疗效指标及安全性指标。结 果 观察组治疗后 90 d 发生脑卒中 3（3. 8）、缺血性脑卒中 3（3. 8）、出血性脑卒中 0 例、心肌梗死 0 例、TIA 1 例 （1. 3%）、全因死亡2例（2. 5%），对照组分别为5例（6. 3%）、5例（6. 3%）、0例、0例、3例（3. 8%）、2例（2. 5%），两组脑 卒中、缺血性脑卒中发生率比较，P 均<0. 05。观察组治疗后 90 d 发生重度出血 0 例、中度出血 0 例、轻度出血 2 例 （2. 5%）、任何出血5例（6. 3%），对照组分别为0例、0例、1例（1. 3%）、4例（5%），两组比较，P均>0. 05。结论 替罗 非班静注联合替格瑞洛、阿司匹林口服可明显降低ANIS 90 d卒中复发率，且不增加中重度出血事件，安全性较高。 [ABSTRACT FROM AUTHOR]

Objective: To study Effect of magnesium sulfate combined with low-dose aspirin in the treatment of preeclampsia and influence of uterine artery blood flow, placental Vascular Endothelial growth factor (VEGF), Matrix Metalloproteinase-9 (MMP-9) expression. Methods: 125 patients with prelampsia who received treatment in our hospital from June 2019 to January 2021 were selected and divided into experimental group (n=63) and control group (n=62) by random number table method. The control group was treated with magnesium sulfate, and the experimental group was treated with low-dose aspirin in addition to the control group. Clinical efficacy, uterine artery blood flow, placental VEGF, MMP-9, blood pressure and adverse pregnancy outcomes were compared between the two groups. Results: After treatment, the total effective rate of the two groups was significantly different (P<0.05); Before treatment, there was no significant difference in uterine artery indexes between experimental group and control group. After treatment, RI, PI and S/D levels in experimental group and control group were increased over time, and the experimental group was higher than the control group, the difference was significant (P<0.05); Before treatment, there were no significant differences in placental VEGF and MMP-9 levels between experimental group and control group. After treatment, the levels of placental VEGF and MMP-9 in experimental group and control group were increased over time, and the levels in experimental group were higher than those in control group, the difference was significant (P<0.05); Before treatment, there was no significant difference in blood pressure between the experimental group and the control group. After treatment, the blood pressure level of both experimental group and control group decreased over time, and the experimental group was lower than the control group, the difference was significant (P<0.05); The incidence of fetal distress, uterine weakness and neonatal asphyxia in experimental group were significantly lower than those in control group (P<0.05). Conclusion: Magnesium sulfate combined with low-dose aspirin is effective in the treatment of preeclampsia, which can effectively improve the levels of uterine artery blood flow, placental VEGF and MMP-9. [ABSTRACT FROM AUTHOR]

为了探究氯吡格雷和阿司匹林联合治疗老年冠心病的临床效果及对血清CRP水平的作用，本研究选取了 60例老年冠心病患者进行随机分组，随机分为两组，其中实验组30例给予氯吡格雷和阿司匹林联合治疗，对照组30例 给予单纯的阿司匹林治疗，比较两组患者的临床效果和血清CRP水平。本文旨在探讨氯吡格雷、阿司匹林联合治疗老 年冠心病的临床效果及对血清CRP水平的作用分析。结果：治疗组心电图改善率、总有效率、临床症状积分均高于对 照组，差异具有统计学意义 (P < 0.05) 。治疗组血脂水平、血小板聚集率和血清CRP水平均较对照组显著降低，差异 具有统计学意义 (P < 0.05) 。结论：氯吡格雷、阿司匹林联合治疗老年冠心病可显著提高患者的治疗效果，同时具 有明显的降低血清CRP水平的作用，值得临床推广应用。 [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Clinical Healthcare is the property of Chinese Journal of Clinical Healthcare and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)